trial was not powered or designed to assess cardiovascular event outcome. it was to prove biologic effect in vivo on cholesterol and safety.
the point of the phase 3 is to assess cv outcomes which need longer term followup and bigger sample size.
this is very good news but i guess the average investor may not realise this and think that it was supposed to show lower cardiovascular events, which is not true.
oh well, their loss
Ann: Positive Results from CSL112 Phase 2b Trial, page-6
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$308.53 |
Change
3.060(1.00%) |
Mkt cap ! $149.0B | |||
| Open | High | Low | Value | Volume |
| $308.99 | $308.99 | $305.97 | $232.7M | 769.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 913 | $307.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $308.59 | 20 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| CSL (ASX) Chart |